Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data

Vivani Medical Inc. (NASDAQ:VANI) on Tuesday reported results from the LIBERATE-1 Phase 1 study of the exenatide GLP-1 implant NPM-115, representing the first-in-human test of the company's proprietary NanoPortal implant technology. Exenatide is sold by AstraZeneca Plc (NASDAQ:AZN) under the brand…